Ann: Breast Cancer Clinical Trial Program Initiated, page-27

There are millions of in-the-money unlisted options @DodgyMinors .
The management team also have good control here .

Major shareholders lead by Merchant Fund; & David Williams ( the Chairman of Polynovo & a wealthy man ), as well as a Hong Kong investor have already converted options they bought off- market that had only had expiry dates of in late 2021 & 2022 !
This trio have also invested many millions of dollars directly into RAC.

So a good amount of money is in RAC coffers already .

Will also not be surprised if more options are converted and money received by the company , on news and scope of trials release .
As indicated in yesterday’s interview of Dr T with Proactive - partnering is most likely for major trials . This has long been stated by this management as what will occur , & also by the former CEO Dr Molloy.

Prof Borje Andersson , preeminent globally famous really, Oncologist, and who is RAC Chief Medical Officer —has the best contacts , and obviously significant capability and base at MD Anderson Centre .
I think partnering will occur for US trial work .

We are very lucky as Race Oncology shareholders !

You never know - if ever they did really need some money , (which they do not ) , we might get a go
But it won’t be within cooee of here imo , and is not very likely , much as we all would like the opportunity.